SCHEMBL206466

SCHEMBL206466

Nc1cccc2c1CC(=O)CC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.52
CD44 P16070 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
PARP1 P09874 1/20 0.41
CYP1A2 P05177 2/20 0.38
TRPV1 Q8NER1 1/20 0.35
CES1 P23141 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
ANPEP P15144 3/20 0.34
IL1RN P18510 1/20 0.34
ERAP2 Q6P179 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10229515 0.86 CD44 (0.48) CYP2A6CD44KDM4EMEN1ALDH1A1
SCHEMBL7333315 0.84 CYP2A6 (0.52) CYP2A6CD44KDM4EMEN1ALDH1A1
SCHEMBL9523617 0.83 CYP1A2 (0.52) CYP2A6CD44KDM4EMEN1ALDH1A1
SCHEMBL1868979 0.80 CYP2A6 (0.52) CYP2A6MEN1KMT2ACYP1A2TRPV1
SCHEMBL30060771 0.78
SCHEMBL20404268 0.78
SCHEMBL5535806 0.78 CYP2A6 (0.54) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL24576685 0.76 CYP2A6 (0.52) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL5836173 0.76 CYP2A6 (0.52) CYP2A6CYP1A2TRPV1CES1AHR
SCHEMBL12430512 0.76 CYP2A6 (0.52) CYP2A6MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250246-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2025-08-07 US disclosed
US-12286414-B2 Method for producing heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2025-04-29 US disclosed
CN-118812481-A Process for producing heterocyclylacetamide derivative 持田制药株式会社 2024-10-22 CN disclosed
EP-4410989-A2 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES Mochida Pharmaceutical Co., Ltd. (JP) 2024-08-07 EP disclosed
EP-4019485-B1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES MOCHIDA PHARM CO LTD (JP) 2024-08-07 EP disclosed
CN-114206847-B Process for producing heterocyclylacetamide derivative 持田制药株式会社 2024-07-16 CN disclosed
EP-4019485-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES Mochida Pharmaceutical Co., Ltd. (JP) 2022-06-29 EP disclosed
EP-4019485-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES Mochida Pharmaceutical Co., Ltd. (JP) 2022-06-29 EP disclosed
CN-114206847-A Process for producing heterocyclylideneacetamide derivative 持田制药株式会社 2022-03-18 CN disclosed
US-20220009898-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2022-01-13 US disclosed
WO-2005040100-A1 TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-05-06 WO disclosed
WO-2005040119-A1 TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-05-06 WO disclosed
EP-1506167-A1 HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES Bayer HealthCare AG (DE) 2005-02-16 EP disclosed
WO-2005002551-A2 VANILLOID RECEPTOR (VR) 1 INHIBITORS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)-MEDIATED PAIN STATES BAYER HEALTHCARE AG (DE) 2005-01-13 WO disclosed
EP-1493438-A1 Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states Bayer HealthCare AG (DE) 2005-01-05 EP disclosed
WO-2004074244-A2 PYRIMIDINE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-09-02 WO disclosed
WO-2004072020-A1 HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-08-26 WO disclosed
WO-2004052845-A1 TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS BAYER HEALTHCARE AG (DE) 2004-06-24 WO disclosed
WO-2004052846-A1 TETRAHYDRO-NAPHTHALENE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-06-24 WO disclosed
WO-2003095420-A1 HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12286414-B2 Method for producing heterocyclidene acetamide derivative COASY, NAAA, AADAC CYP2A6 217/4885CD44 4804/4885KDM4E 3380/4885
US-20220009898-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE COASY, NAAA, AADAC CYP2A6 217/4885CD44 4804/4885KDM4E 3380/4885
US-20250250246-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE COASY, NAAA, AADAC CYP2A6 217/4885CD44 4804/4885KDM4E 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.